Metformin as An ADD on therapy in the treatment of hepatitis C virus Egyptian patients / Hossam Eldin Shaaban ; Supervised Taher Elzanaty , Ayman Foda , Sameh Seif Eldin
Material type:
- استخدام عقار الميتفورمين كعلاج إضافي لمرضى الالتهاب الكبدي الفيروسي سي المصريين [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.18.Ph.D.2013.Ho.S (Browse shelf(Opens below)) | Not for loan | 01010110063554000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.11.18.Ph.D.2013.Ho.S (Browse shelf(Opens below)) | 63554.CD | Not for loan | 01020110063554000 |
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
HCV is a major health problem in Egypt. Combined therapy with pegylated interferon and ribavirin is the only evidence based treatment to HCV genotype 4. Insulin resistance is linked to non response to combined therapy. The study was carried out to study the effect of adding metfurmin to the combined therapy in patients with insulin resistance. Statistical studies were carried out on two groups. One group took triple therapy with pegylated interferon, ribavirin, and metfurmin. The second group took combined therapy. Statistical analysis revealed no significant dffirence between the two groups at week 72 (SVR)
Issued also as CD
There are no comments on this title.